An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
C4 Therapeutics announced an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant includes non-qualified stock options to purchase 146,880 shares of common stock, with the options vesting over a four-year period. This grant was approved by the Company's Board of Directors and serves as an inducement for the employee to join C4 Therapeutics.
C4 Therapeutics ha annunciato l'assegnazione di un incentivo a un nuovo dipendente ai sensi della Regola di Quotazione Nasdaq 5635(c)(4). L'incentivo include opzioni su azioni non qualificate per l'acquisto di 146,880 azioni ordinarie, con un periodo di maturazione delle opzioni di quattro anni. Questo incentivo è stato approvato dal Consiglio di Amministrazione della Società e serve come incentivo per il dipendente ad unirsi a C4 Therapeutics.
C4 Therapeutics anunció un otorgamiento de incentivos a un nuevo empleado bajo la Regla de Listado de Nasdaq 5635(c)(4). La concesión incluye opciones de acciones no calificadas para comprar 146,880 acciones ordinarias, con las opciones adquiriendo su validez a lo largo de un período de cuatro años. Esta concesión fue aprobada por el Consejo de Directores de la empresa y actúa como un incentivo para que el empleado se una a C4 Therapeutics.
C4 테라퓨틱스는 나스닥 상장규칙 5635(c)(4)에 따라 새로운 직원에게 유인 부여를 발표했습니다. 이 부여는 일반 주식 146,880주를 매수할 수 있는 자격이 없는 주식 옵션을 포함하며, 옵션은 4년 동안 귀속됩니다. 이 부여는 회사 이사회에 의해 승인되었으며, 직원이 C4 테라퓨틱스에 합류하도록 유인하는 역할을 합니다.
C4 Therapeutics a annoncé une attribution d'incitation à un nouvel employé conformément à la Règle de cotation Nasdaq 5635(c)(4). L'attribution comprend des options d'achat d'actions non qualifiées pour 146,880 actions ordinaires, avec des options acquérant sur une période de quatre ans. Cette attribution a été approuvée par le conseil d'administration de l'entreprise et sert d'incitation pour que l'employé rejoigne C4 Therapeutics.
C4 Therapeutics hat eine Anreizzuwendung für einen neuen Mitarbeiter gemäß der Nasdaq-Listing-Regel 5635(c)(4) bekanntgegeben. Die Zuwendung umfasst nichtqualifizierte Aktienoptionen für den Kauf von 146,880 Stammaktien, wobei die Optionen über einen Zeitraum von vier Jahren gewährt werden. Diese Zuteilung wurde vom Vorstand der Firma genehmigt und dient als Anreiz für den Mitarbeiter, sich C4 Therapeutics anzuschließen.
Positive
None.
Negative
None.
WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 146,880 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on April 29, 2024 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grant has an exercise price per share that is equal to the closing price of C4T’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the first-year anniversary of the employee’s start date, with the remainder of the shares vesting in twelve equal quarterly installments thereafter, subject to the employee’s continued employment with C4T through each vesting date.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
Contacts:
Investors: Courtney Solberg Senior Manager, Investor Relations CSolberg@c4therapeutics.com
C4 Therapeutics announced an inducement grant under Nasdaq Listing Rule 5635(c)(4).
How many shares of common stock can be purchased through the grant?
The grant includes options to purchase 146,880 shares of the Company's common stock.
When was the grant made?
The grant was made on April 29, 2024.
How will the options vest?
The options will vest over a four-year period, with 25% vesting on the first-year anniversary of the employee's start date, and the remaining shares vesting in twelve equal quarterly installments thereafter.
What is the purpose of the grant?
The grant serves as a material inducement for the new employee to enter into employment with C4 Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4).
c4 therapeutics is an early stage drug discovery company whose mission is to harness targeted protein degradation to develop therapeutics for a broad range of diseases. the centerpiece of our approach is the degronimid® platform, which enables highly selective small molecule binders to target disease causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system.
